Completed PHASE4 INTERVENTIONAL 2-arm NCT01453179

Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) (LEIDA 2)

Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma

Sponsor: Accovion GmbH

Conditions Actinic Keratosis

Interventions Diclofenac Imiquimod

Updated 7 times since 2017 Last updated: Feb 4, 2022 Started: Oct 31, 2011 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Actinic Keratosis and is currently completed. Accovion GmbH leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Mar 2022 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Accovion GmbH
MEDA Pharma GmbH & Co. KG
Siro Clinpharm Germany GmbH (until June 2013)

Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Berlin, Germany , Dülmen, Germany , Germering, Germany , Graz, Austria , Magdeburg, Germany , Mahlow, Germany , Mainz, Germany , Maria Enzersdorf, Austria , Markkleeberg, Germany and 6 more locations